SciMed Solutions

04/09/2026

"One of the very common approaches in drug discovery is something called docking..." - Chuck Reynolds, Founder of Gfree Bio

In the latest episode of the SciMed Biotech Podcast, Dr. Charles Reynolds explains how docking simulations allow scientists to test how potential drug molecules might bind to their targets before they’re ever synthesized in the lab.

By modeling these interactions computationally, researchers can better understand molecular behavior and design more effective drug candidates.

Listen to the full episode here: https://www.scimed.io/news/chuck-reynolds-gfree-bio

hashtag hashtag hashtag

04/02/2026

Drug discovery is often imagined as a purely experimental process happening in the lab.

But today, many of the most important decisions happen inside a computer first.

In the latest episode of the SciMed Biotech Podcast, we sat down with Dr. Chuck Reynolds, founder of Gfree Bio, to discuss how computational chemistry is helping scientists design better drugs before they ever synthesize them.

We discuss how molecular modeling and docking simulations help scientists predict how drugs interact with proteins, guide medicinal chemistry decisions, and accelerate the iterative process of drug discovery. Chuck also shares how advances in computing power and machine learning are expanding what’s possible in computational drug design.

If you’re interested in the intersection of biotech, computational modeling, and drug discovery, this episode provides a great overview of how these tools are shaping modern pharma R&D.

Listen to the episode here: https://www.scimed.io/news/chuck-reynolds-gfree-bio

03/26/2026

AI in healthcare gets a lot of attention for big ideas about replacing doctors. In reality some of the most useful applications are much simpler.

During our conversation on the SciMed Biotech Podcast, Paul Nanda shared how his team has been using AI powered documentation through Microsoft DAX Copilot within their Epic system.

The tool listens during the visit and generates the clinical note automatically.

It may only save two or three minutes per patient chart. But when a physician sees fifty patients in a day that can add up to nearly two hours saved.

What stood out in the conversation was that the value is not just efficiency. It is time. Less time typing. More time listening to patients. More time explaining care.

Listen to the conversation on our website 🎧
https://scimed.io/news/paul-nanda-tgh-urgent-care-official

03/19/2026

Urgent care didn’t grow simply because it was convenient. It grew because patients needed another option when they could not quickly access primary care.

On the SciMed Biotech Podcast we spoke with Paul Nanda, Chief Medical Officer of TGH Urgent Care powered by Fast Track, about how urgent care emerged to fill that gap and how technology is now pushing the model even further.

Remote diagnostic tools that cost only a few hundred dollars can now help physicians examine a patient’s eyes, ears, throat, heart, lungs, and vital signs from a distance. What once required expensive telemedicine kiosks is becoming something patients can use right from home.

It is a reminder that urgent care is no longer only a place you go. It is gradually becoming a more distributed way to deliver care while still maintaining quality clinical exams.

Listen in on our website 🎧
https://scimed.io/news/paul-nanda-tgh-urgent-care-official

Dr. Paul Nanda has delivered babies in Zimbabwe, supported displaced Ukrainian refugees in Warsaw, and now leads urgent care initiatives across the Tampa Bay region. In this episode, he shares how his global medical missions—from Haiti to New Zealand—have shaped his perspective on healthcare acc...

03/12/2026

In this episode of the SciMed Biotech Podcast, Shubhranshu Gupta, PhD (CEO & Founder of Immumem Therapeutics) explains why persistence — not just cytotoxicity — may be the limiting factor for cell therapies in solid tumors.

We dig into what actually causes TN/NK cells to fail in the tumor microenvironment, how metabolic exhaustion and ECM barriers limit durability, and why training immune cells for functional memory could be a meaningful shift in how relapse is addressed.

The conversation also touches on how iPSC-derived platforms and ML-guided modeling are being used to design more durable immunotherapies from the start.

Listen to the full episode here:
https://www.scimed.io/news/shubhranshu-gupta-immumem-therapeutics

03/05/2026

Most cell therapies struggle in solid tumors for the same reasons: limited pe*******on, rapid exhaustion, and high relapse rates. In this episode of the SciMed Biotech Podcast, I sat down with Shubhranshu Gupta, PhD, CEO & Founder of Immumem Therapeutics, to unpack how engineering true immune memory into TN/NK cells could change what’s possible in solid tumor immunotherapy.

We get into why current cell therapies break down in the tumor microenvironment, how ECM barriers and metabolic exhaustion limit persistence, and how Immumem is training immune cells to behave more like memory cells rather than short-lived effectors. Shubhranshu also shares how iPSC-derived cells enable scalable, off-the-shelf approaches, and how machine learning is being used to better connect ex vivo results with predicted in vivo performance.

Listen to the full episode here:
https://www.scimed.io/news/shubhranshu-gupta-immumem-therapeutics

02/19/2026

To explore how T-cell receptor therapies are reshaping cancer immunotherapy, we spoke with Dr. Joanna Brewer, Chief Scientific Officer of Adaptimmune, on a prior episode of the SciMed Biotech Podcast.

Dr. Brewer walks through how Adaptimmune’s work on SPEAR T-cell therapies is designed to leverage engineered T-cell receptors to target cancer-specific peptides, and what it takes to translate these approaches from discovery into clinical programs. We discuss the development of TCR-based cell therapies, lessons from patient outcomes, and how translational research shapes next-generation approaches in the field.

For listeners interested in the mechanics, challenges, and future direction of cell therapy in oncology, this episode offers a clear and research-driven perspective from someone deeply embedded in the science.

Listen on the SciMed website.

🎧 https://scimed.io/news/joanna-brewer-scimed-biotech-podcast

Brace yourself for an exhilarating journey into the world of cutting-edge cancer immunotherapy with Dr. Joanna Brewer, Chief Scientific Officer of Adaptimmune!

02/12/2026

In a prior episode of the SciMed Biotech Podcast, we spoke with Paul Marshall, CEO of Rapid Fluidics, about how microfluidics development can be dramatically accelerated without sacrificing precision.

Paul shares how advances in rapid prototyping, 3D printing, and CAD-driven design are changing the way microfluidic devices are built—reducing development timelines and costs that traditionally slow life science and biotech innovation.

We discuss why speed matters so much in early-stage product development, how design iteration impacts downstream scalability, and what engineers and founders should consider when moving from concept to functional device.

For anyone working at the intersection of engineering and biotech, this episode offers a practical look at how microfluidics can move faster—and smarter.

Listen now on our website.

🔗 https://scimed.io/news/paul-marshall-rapid-fluidics

In this episode of the SciMed Biotech Podcast , we're joined by Paul Marshall , a trailblazer in the field of microfluidics and the CEO of Rapid Fluidics . Paul shares his journey from an engineering consultant to leading a company at the forefront of microfluidic technology. With his deep expert

02/05/2026

In a prior episode of the SciMed Biotech Podcast, we spoke with Matthew Gdovin, Founder and Chief Science Officer of Vitanova Biomedical, about a cancer treatment approach built around light-activated intracellular acidosis (LAIA).

Matthew breaks down how Vitanova’s platform uses upconverting nanoparticles and deep-penetrating light to trigger intracellular processes that selectively induce cancer cell death. We discuss why intracellular pH regulation is a compelling therapeutic target, how light activation enables precise control, and what it takes to move a physics-driven therapy from the lab toward clinical application.

If you’re interested in how emerging cancer therapies are being engineered at the cellular level, this episode is worth revisiting.

Listen now on our website.

🎧 https://scimed.io/news/matthew-gdovin-vitanova-biomedical

This episode features an exciting conversation with Matthew Gdovin, the Founder and Chief Science Officer of Vitanova Biomedical. Delve into the technology behind Vitanova’s cancer treatments as Matthew explains their proprietary light-activated intracellular acidosis (LAIA) therapy, which targets...

12/11/2025

“Personalized repetitive TMS uses spectral EEG data to guide stimulation across multiple cortical regions, and we update the protocol weekly based on quantitative measurements..."

In this episode, Keerthy Sunder explains how neuromodulation is evolving beyond fixed-target TMS. Instead of stimulating a single location with a static protocol, spectral EEG and weekly data inputs allow clinicians to adjust frequency, coil position, and cortical targets dynamically — creating a measurement-driven pathway for treatment-resistant conditions.

We discuss what this means for psychiatry as a field: the move from “one-size-fits-all” interventions toward individualized neurocircuitry-based care, and how these methods are being adopted in clinical environments today.

Listen to the full discussion on the SciMed website: https://www.scimed.io/news/keerthy-sunder

12/04/2025

Today’s guest on the SciMed Biotech Podcast is Keerthy Sunder, Chief Medical Officer of Karma Doctors & Associates and a leading researcher in neuromodulation, TMS, and integrative psychiatry.

In this episode, Dr. Sunder breaks down why current psychiatric standards — reducing depression or anxiety scores — don’t fully capture brain health or long-term outcomes. He outlines a model that combines evidence-based neuromodulation, metabolic and hormonal factors, neuroplasticity, and behavioral science to address treatment-resistant conditions and optimize cognitive function.

We dive into:

👨‍⚕️ Where traditional psychiatry falls short in treatment-resistant patients
🤖 The mechanistic role of TMS and neurofeedback in reshaping neural circuits
🧠 The gut-brain and hormone-brain pathways that influence mood and cognition

If you’re interested in how psychiatry is evolving, this conversation is worth a listen.

Listen now on the SciMed website: https://www.scimed.io/news/keerthy-sunder